Sökning: "myeloid leukemia"
Visar resultat 1 - 5 av 195 avhandlingar innehållade orden myeloid leukemia.
1. Targeting residual malignant cells in myeloid leukemia
Sammanfattning : Malignant cells persisting during treatment prevent cure in many patients with myeloid leukemia. In acute myeloid leukemia (AML), the failure to eradicate the leukemic clone during conventional chemotherapy is associated with leukemic relapse, mostly with dismal survival outcome. LÄS MER
2. Immunotherapy and immunosuppression in myeloid leukemia
Sammanfattning : Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are potentially life-threatening blood cancers characterized by the expansion of malignant myeloid cells in bone marrow and other organs. This thesis aimed at contributing to the understanding of the role of natural killer (NK) cells in AML and CMML with focus on the potential impact of the immunosuppression exerted by reactive oxygen species (ROS) formed by the myeloid cell NOX2 enzyme. LÄS MER
3. Chronic myeloid leukemia and cancer
Sammanfattning : Background Chronic myeloid leukemia (CML) is a relatively rare hematological malignancy with a constant incidence of approximately 90 new cases each year in Sweden (0.9 cases/100 000 inhabitants). The etiology is largely unknown but high doses of ionizing radiation are a known but rare risk factor. LÄS MER
4. Perinatal Risk Factors for Childhood Leukemia
Sammanfattning : The aim of the studies described in this thesis was to assess the association between certain perinatal factors and the risk of childhood lymphatic and myeloid leukemia and infant leukemia. The five studies presented were all conducted in Sweden as population-based case-control studies. LÄS MER
5. Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia
Sammanfattning : Chronic myeloid leukemia (CML) is caused by the transformation of a primitive hematopoietic cell by the BCR/ABL1 fusion gene that is formed through the chromosomal translocation t(9;22). CML is currently successfully treated with tyrosine kinase inhibitors targeting the ABL1 kinase domain. LÄS MER